

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents, with one being Baqsimi (defined as 1 claim each in the last 12 months):
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

Required Documentation

Laboratory Results:

Progress Notes:

MedWatch Form:

Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

1. Evidence-Based Medicine and Fiscal Analysis: "Glucagon Products – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; November 2019
2. Evidence-Based Medicine Analysis: "Glucagon Products", UMKC-DIC; October 2019.
3. Baqsimi (glucagon) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
4. Gvoke (glucagon) [package insert]. Chicago, IL: Xeris Pharmaceuticals, Inc.; 2019.
5. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2019.
6. USPDI, Micromedex; 2019.
7. Drug Facts and Comparisons On-line; 2019.

SmartPA PDL Proposal Form

© 2019 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.